Real-World, Long-Term Outcomes of Nivolumab Therapy for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck and Impact of the Magnitude of Best Overall Response: A Retrospective Multicenter Study of 88 Patients

SIMPLE SUMMARY: No real-world, long-term outcomes of immunotherapy with nivolumab for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) have yet been reported. Furthermore, the prognostic impact of the best overall response (BOR) of this therapy remains unclear. We con...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsuki, Takashi, Okamoto, Isaku, Fushimi, Chihiro, Takahashi, Hideaki, Okada, Takuro, Kondo, Takahito, Sato, Hiroki, Ito, Tatsuya, Tokashiki, Kunihiko, Tsukahara, Kiyoaki, Hanyu, Kenji, Masubuchi, Tatsuo, Tada, Yuichiro, Miura, Kouki, Omura, Go, Sawabe, Michi, Kawakita, Daisuke, Yamashita, Taku
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7699139/
https://www.ncbi.nlm.nih.gov/pubmed/33218183
http://dx.doi.org/10.3390/cancers12113427

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7699139/
https://www.ncbi.nlm.nih.gov/pubmed/33218183
http://dx.doi.org/10.3390/cancers12113427

Ejemplares similares